These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36379958)

  • 1. Two-component vaccine consisting of virus-like particles displaying hepatitis C virus envelope protein 2 oligomers.
    Prentoe J; Janitzek CM; Velázquez-Moctezuma R; Soerensen A; Jørgensen T; Clemmensen S; Soroka V; Thrane S; Theander T; Nielsen MA; Salanti A; Bukh J; Sander AF
    NPJ Vaccines; 2022 Nov; 7(1):148. PubMed ID: 36379958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered Glycosylation Patterns Increase Immunogenicity of a Subunit Hepatitis C Virus Vaccine, Inducing Neutralizing Antibodies Which Confer Protection in Mice.
    Li D; von Schaewen M; Wang X; Tao W; Zhang Y; Li L; Heller B; Hrebikova G; Deng Q; Ploss A; Zhong J; Huang Z
    J Virol; 2016 Dec; 90(23):10486-10498. PubMed ID: 27630242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virus-Like Particles Containing the E2 Core Domain of Hepatitis C Virus Generate Broadly Neutralizing Antibodies in Guinea Pigs.
    McGregor J; Hardy JM; Lay CS; Boo I; Piontek M; Suckow M; Coulibaly F; Poumbourios P; Center RJ; Drummer HE
    J Virol; 2022 Mar; 96(5):e0167521. PubMed ID: 34986001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization With a Subunit Hepatitis C Virus Vaccine Elicits Pan-Genotypic Neutralizing Antibodies and Intrahepatic T-Cell Responses in Nonhuman Primates.
    Li D; Wang X; von Schaewen M; Tao W; Zhang Y; Heller B; Hrebikova G; Deng Q; Sun Q; Ploss A; Zhong J; Huang Z
    J Infect Dis; 2017 Jun; 215(12):1824-1831. PubMed ID: 28398489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Nanoparticle-Based Hepatitis C Virus Vaccine With Enhanced Potency.
    Yan Y; Wang X; Lou P; Hu Z; Qu P; Li D; Li Q; Xu Y; Niu J; He Y; Zhong J; Zhong H
    J Infect Dis; 2020 Mar; 221(8):1304-1314. PubMed ID: 31074790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Hepatitis C Virus DNA Vaccine Encoding a Secreted, Oligomerized Form of Envelope Proteins Is Highly Immunogenic and Elicits Neutralizing Antibodies in Vaccinated Mice.
    Masavuli MG; Wijesundara DK; Underwood A; Christiansen D; Earnest-Silveira L; Bull R; Torresi J; Gowans EJ; Grubor-Bauk B
    Front Immunol; 2019; 10():1145. PubMed ID: 31178869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice.
    Pihl AF; Feng S; Offersgaard A; Alzua GP; Augestad EH; Mathiesen CK; Jensen TB; Krarup H; Law M; Prentoe J; Christensen JP; Bukh J; Gottwein JM
    J Hepatol; 2022 May; 76(5):1051-1061. PubMed ID: 34990750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified E2 Glycoprotein of Hepatitis C Virus Enhances Proinflammatory Cytokines and Protective Immune Response.
    Vijayamahantesh V; Patra T; Meyer K; Alameh MG; Reagan EK; Weissman D; Ray R
    J Virol; 2022 Jun; 96(12):e0052322. PubMed ID: 35612312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.
    Law JLM; Logan M; Wong J; Kundu J; Hockman D; Landi A; Chen C; Crawford K; Wininger M; Johnson J; Mesa Prince C; Dudek E; Mehta N; Tyrrell DL; Houghton M
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29540595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.
    Wong JA; Bhat R; Hockman D; Logan M; Chen C; Levin A; Frey SE; Belshe RB; Tyrrell DL; Law JL; Houghton M
    J Virol; 2014 Dec; 88(24):14278-88. PubMed ID: 25275133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs.
    Vietheer PT; Boo I; Gu J; McCaffrey K; Edwards S; Owczarek C; Hardy MP; Fabri L; Center RJ; Poumbourios P; Drummer HE
    Hepatology; 2017 Apr; 65(4):1117-1131. PubMed ID: 27997681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey.
    Wang X; Yan Y; Gan T; Yang X; Li D; Zhou D; Sun Q; Huang Z; Zhong J
    Gut; 2019 Jan; 68(1):140-149. PubMed ID: 29180585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Head-to-Head Comparison of Modular Vaccines Developed Using Different Capsid Virus-Like Particle Backbones and Antigen Conjugation Systems.
    Fredsgaard L; Goksøyr L; Thrane S; Aves KL; Theander TG; Sander AF
    Vaccines (Basel); 2021 May; 9(6):. PubMed ID: 34063871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
    Johnson J; Freedman H; Logan M; Wong JAJ; Hockman D; Chen C; He J; Beard MR; Eyre NS; Baumert TF; Tyrrell DL; Law JLM; Houghton M
    J Virol; 2019 Nov; 93(22):. PubMed ID: 31462563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens.
    Prentoe J; Janitzek CM; Velázquez-Moctezuma R; Goksøyr L; Olsen RW; Fanalista M; Augestad EH; Thrane S; Pihl AF; Gottwein JM; Sander AF; Bukh J
    PLoS One; 2021; 16(7):e0255336. PubMed ID: 34329365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.
    Deng K; Liu R; Rao H; Jiang D; Wang J; Xie X; Wei L
    PLoS One; 2015; 10(9):e0138756. PubMed ID: 26406225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine.
    Beaumont E; Patient R; Hourioux C; Dimier-Poisson I; Roingeard P
    Hepatology; 2013 Apr; 57(4):1303-13. PubMed ID: 23150224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol.
    Freyschmidt EJ; Alonso A; Hartmann G; Gissmann L
    Antivir Ther; 2004 Aug; 9(4):479-89. PubMed ID: 15456078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes.
    Gu J; Hardy J; Boo I; Vietheer P; McCaffrey K; Alhammad Y; Chopra A; Gaudieri S; Poumbourios P; Coulibaly F; Drummer HE
    J Virol; 2018 May; 92(9):. PubMed ID: 29467319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel adeno‑associated virus‑based genetic vaccines encoding hepatitis C virus E2 glycoprotein elicit humoral immune responses in mice.
    Zhu F; Wang Y; Xu Z; Qu H; Zhang H; Niu L; Xue H; Jing D; He H
    Mol Med Rep; 2019 Feb; 19(2):1016-1023. PubMed ID: 30569131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.